Perpetual Ltd’s Alnylam Pharmaceuticals ALNY Stock Holding History

Perpetual Ltd’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$819K	Buy	2,722 +32	+1%	+$9.65K	0.01%	251
2026 Q1	$890K	Sell	2,690 -2,349	-47%	-$799K	0.01%	231
2025 Q4	$2M	Buy	+5,039	New	+$2.23M	0.03%	179
2025 Q2	–	Sell	-3,718	Closed	-$1M	–	418
2025 Q1	$1M	Sell	3,718 -5,213	-58%	-$1.34M	0.01%	243
2024 Q4	$2.1M	Buy	8,931 +4,819	+117%	+$1.27M	0.02%	191
2024 Q3	$1.13M	Buy	+4,112	New	+$1.07M	0.01%	250

Other funds holding ALNY

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

FAF

Fjarde Ap-fonden Stockholm, Sweden $20.9B AUM 36.93% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Asset Management One Tokyo, Japan $39B AUM 37.51% 1-Year Est. Return

MIF

Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return

Perpetual Ltd's ALNY Position: Q2 2026 in Review

Perpetual Ltd increased its Alnylam Pharmaceuticals (ALNY) stake by 1.2% in Q2 2026, buying an estimated $9.65K and bringing the position to 2,722 shares worth $819K. The position accounts for 0.01% of the portfolio, ranked #251.

Perpetual Ltd first reported a position in ALNY in Q3 2024 and has held it in 6 quarters since. The position peaked at $2.1M in Q4 2024. 211 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Perpetual Ltd held 2,722 shares of Alnylam Pharmaceuticals worth $819K as of Q2 2026.
Perpetual Ltd bought 32 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $9.65K.
Alnylam Pharmaceuticals made up 0.01% of Perpetual Ltd's portfolio in Q2 2026, its #251 holding.
Perpetual Ltd first reported a position in Alnylam Pharmaceuticals in Q3 2024 and has held it in 6 quarters since.
Perpetual Ltd's Alnylam Pharmaceuticals position peaked at $2.1M in Q4 2024.
211 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Perpetual Ltd's 13F filing for Q2 2026, filed 15 Jul 2026.